Informasjon Tiden det tar fra du smittes til du blir syk, inkubasjonstiden, er vanligvis 4-7 dager (med variasjon fra 1-12 dager).
Chikungunyavirus-sykdom
Chikungunyavirussykdom, eller Chikungunyafeber, er en myggoverført virussykdom med utslett, feber og eventuelt leddsymptomer. Det er en selvbegrensende sykdom.
Sist oppdatert:
25. juli 2022
Vil du vite mer
Dette dokumentet er basert på det profesjonelle dokumentet Chikungunyavirus-sykdom . Referanselisten for dette dokumentet vises nedenfor
Referanser
- Vu DM, Jungkind D, Angelle Desiree LaBeaud. Chikungunya Virus. Clin Lab Med. 2017;37(2):371-382. PubMed
- Smittevernveilederen. Chikungunyavirus-sykdom - veileder for helsepersonell. Folkehelseinstituttet, sist oppdatert 13.01.2018.
- Morens DM, Fauci AS. Chikungunya at the door--déjà vu all over again? N Engl J Med 2014; 371:885. New England Journal of Medicine
- Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 2015; 372:1231. New England Journal of Medicine
- Gerardin P, Couderc T, Bintner M, et al. Chikungunya virus - associated encephalitis. Neurology 2015. doi:10.1212/WNL.0000000000002234
- Parola P, de Lamballerie X, Jourdan J, et al. Novel Chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis 2006; 12: 1493-9. PubMed
- Centers for Disease Control and Prevention. Chikungunya Virus. Symptoms, Diagnosis and Treatment. 2022. www.cdc.gov
- Charrel RN, de Lamballerie X,Raoult D. Chikungunya outbreaks - the globalization of vectorborne diseases. N Engl J Med 2007; 356: 769-71. PubMed
- Simon F, Savini H, Parola P. Chikungunya: a paradigm of emergence and globalization of vector-borne diseases. Med Clin North Am 2008; 92:1323. PubMed
- Ferreira AC, Reis PA, de Freitas CS, et al. Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. Antimicrob Agents Chemother. 2018. pmid:30455237 PubMed
- Schneider M, Narciso-Abraham M, Hadl S, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2023. doi:10.1016/S0140-6736(23)00641-4 DOI